

Bagarazzi Mark  
Form 4  
March 13, 2018

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Bagarazzi Mark

2. Issuer Name and Ticker or Trading Symbol  
INOVIO PHARMACEUTICALS, INC. [INO]

5. Relationship of Reporting Person(s) to Issuer  
  
(Check all applicable)  
  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
Chief Medical Officer

(Last) (First) (Middle)  
660 W. GERMANTOWN PIKE,  
SUITE 110  
  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
03/09/2018

PLYMOUTH MEETING, PA 19462

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
|                                 |                                      |  | Code                           | V   | Amount or Price   |  |                                   |
| Common Stock                    | 03/09/2018                           |  | M                              |   | 25,000 A <u>(1)</u>   | 73,628   | D                                 |
| Common Stock                    | 03/09/2018                           |  | F <sup>(2)</sup>               |   | 6,896 D \$ 4.51   | 66,732   | D                                 |
| Common Stock                    | 03/10/2018                           |  | M                              |   | 20,434 A <u>(3)</u>   | 87,166   | D                                 |
| Common Stock                    | 03/10/2018                           |  | F <sup>(4)</sup>               |   | 5,653 D \$ 4.51   | 81,513   | D                                 |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.



## Edgar Filing: Bagarazzi Mark - Form 4

will vest on March 10, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both.

- (4) The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (3) herein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.